These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 9339481)
1. Development of a Tier I screening battery for detecting endocrine-active compounds (EACs). Cook JC; Kaplan MA; Davis LG; O'Connor JC Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):60-8. PubMed ID: 9339481 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Tier I screening battery for detecting endocrine-active compounds (EACs) using the positive controls testosterone, coumestrol, progesterone, and RU486. O'Connor JC; Davis LG; Frame SR; Cook JC Toxicol Sci; 2000 Apr; 54(2):338-54. PubMed ID: 10774816 [TBL] [Abstract][Full Text] [Related]
3. An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs). O'Connor JC; Cook JC; Slone TW; Makovec GT; Frame SR; Davis LG Toxicol Sci; 1998 Nov; 46(1):45-60. PubMed ID: 9928668 [TBL] [Abstract][Full Text] [Related]
4. Sensitivity of a Tier I screening battery compared to an in utero exposure for detecting the estrogen receptor agonist 17 beta-estradiol. O'Connor JC; Frame SR; Biegel LB; Cook JC; Davis LG Toxicol Sci; 1998 Aug; 44(2):169-84. PubMed ID: 9742655 [TBL] [Abstract][Full Text] [Related]
5. Detection of dopaminergic modulators in a tier I screening battery for identifying endocrine-active compounds (EACs). O'Connor JC; Davis LG; Frame SR; Cook JC Reprod Toxicol; 2000; 14(3):193-205. PubMed ID: 10838120 [TBL] [Abstract][Full Text] [Related]
6. Detection of the environmental antiandrogen p,p-DDE in CD and long-evans rats using a tier I screening battery and a Hershberger assay. O'Connor JC; Frame SR; Davis LG; Cook JC Toxicol Sci; 1999 Sep; 51(1):44-53. PubMed ID: 10496676 [TBL] [Abstract][Full Text] [Related]
7. Detection of thyroid toxicants in a tier I screening battery and alterations in thyroid endpoints over 28 days of exposure. O'Connor JC; Frame SR; Davis LG; Cook JC Toxicol Sci; 1999 Sep; 51(1):54-70. PubMed ID: 10496677 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs). O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364 [TBL] [Abstract][Full Text] [Related]
9. An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators. O'Connor JC; Cook JC; Craven SC; Van Pelt CS; Obourn JD Fundam Appl Toxicol; 1996 Oct; 33(2):182-95. PubMed ID: 8921337 [TBL] [Abstract][Full Text] [Related]
10. Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery. Powlin SS; Cook JC; Novak S; O'Connor JC Toxicol Sci; 1998 Nov; 46(1):61-74. PubMed ID: 9928669 [TBL] [Abstract][Full Text] [Related]
11. Endocrine active compounds: from biology to dose response assessment. Barton HA; Andersen ME Crit Rev Toxicol; 1998 Jul; 28(4):363-423. PubMed ID: 9711433 [TBL] [Abstract][Full Text] [Related]
12. Use of the laboratory rat as a model in endocrine disruptor screening and testing. Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681 [TBL] [Abstract][Full Text] [Related]
13. A repeated 28-day oral dose toxicity study of methoxychlor in rats, based on the 'enhanced OECD test guideline 407' for screening endocrine-disrupting chemicals. Okazaki K; Okazaki S; Nishimura S; Nakamura H; Kitamura Y; Hatayama K; Nakamura A; Tsuda T; Katsumata T; Nishikawa A; Hirose M Arch Toxicol; 2001 Nov; 75(9):513-21. PubMed ID: 11760811 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the primary humoral immune response following exposure of male rats to 17beta-estradiol or flutamide for 15 days. Ladics GS; Smith C; Nicastro SC; Loveless SE; Cook JC; O'Connor JC Toxicol Sci; 1998 Nov; 46(1):75-82. PubMed ID: 9928670 [TBL] [Abstract][Full Text] [Related]
15. Beyond screening: problems and prospects for risk characterization of endocrine disruptors. Rhomberg L Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):74-9. PubMed ID: 9339483 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of endocrine disruptor screening tests in detecting anti-estrogenic effects downstream of receptor-ligand interactions. Takeyoshi M; Yamasaki K; Sawaki M; Nakai M; Noda S; Takatsuki M Toxicol Lett; 2002 Jan; 126(2):91-8. PubMed ID: 11751013 [TBL] [Abstract][Full Text] [Related]
17. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps. Gray LE; Ostby J; Wilson V; Lambright C; Bobseine K; Hartig P; Hotchkiss A; Wolf C; Furr J; Price M; Parks L; Cooper RL; Stoker TE; Laws SC; Degitz SJ; Jensen KM; Kahl MD; Korte JJ; Makynen EA; Tietge JE; Ankley GT Toxicology; 2002 Dec; 181-182():371-82. PubMed ID: 12505339 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a 15-day screening assay using intact male rats for identifying antiandrogens. O'Connor JC; Frame SR; Ladics GS Toxicol Sci; 2002 Sep; 69(1):92-108. PubMed ID: 12215663 [TBL] [Abstract][Full Text] [Related]
19. Endocrine disrupters--testing strategies to assess human hazard. Baker VA Toxicol In Vitro; 2001; 15(4-5):413-9. PubMed ID: 11566572 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a 15-day screening assay using intact male rats for identifying steroid biosynthesis inhibitors and thyroid modulators. O'Connor JC; Frame SR; Ladics GS Toxicol Sci; 2002 Sep; 69(1):79-91. PubMed ID: 12215662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]